DOCSLIB.ORG

Jefferies 2019 Global Healthcare Conference

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Jefferies 2019 Global Healthcare Conference Jefferies 2019 Global Healthcare Conference You are invited to attend the Jefferies 2019 Global Healthcare Conference taking place June 4-7 at the Grand Hyatt in New York City. Following the sugccess of our 2018 conference, with over 400 participating companies and 2,700 attendees, we will again feature an extensive range of public & private healthcare companies across AGENDA the Biopharmaceuticals, Life Sciences, Healthcare Services, Healthcare IT and Medical Technology JUNE 4-7, 2019 sectors. This global gathering of leading executives, institutional investors, private equity investors and VCs will address near- and long-term investment opportunities and discuss the mechanisms driving Grand Hyatt healthcare in the U.S. and internationally. New York, NY The four-day conference will be comprised of company presentations, Q&A breakout sessions, keynotes & thematic panels. Company management teams and investors will also have the opportunity to participate in 1x1 and small group meetings. To add this conference to your Microsoft Outlook calendar, click here. REGISTRATION: Please contact your Jefferies representative PARTICIPATING COMPANIES: www.jefferies.com/060419 HOTEL INFORMATION: Jefferies has reserved a block of rooms at the Grand Hyatt New York (109 E. 42nd Street at Grand Central Terminal) at a negotiated rate of $445 per night (plus tax). Rooms are based on availability and reservations must be made by Monday, May 13 in order to guarantee the conference rate. Please note that rooms must be cancelled by 3pm EST at least 72 hours prior to arrival. To make a reservation, please click here. For any questions, you can call the hotel directly at 1-800-233-1234. QUESTIONS: [email protected] © 2019 Jefferies LLC. Member SIPC. AGENDA TUESDAY, JUNE 4, 2019 Jefferies 2019 Global Healthcare Conference BALLROOM 1 BALLROOM 2 BALLROOM 3 BALLROOM 4 BALLROOM 5 MOROSCO IMPERIAL BREAKOUT: URIS BREAKOUT: JUILLIARD BREAKOUT: BROADWAY BREAKOUT: CARNEGIE HALL BREAKOUT: ALVIN BREAKOUT: PLYMOUTH BREAKOUT: BOOTH 7:30 AM Breakfast & Registration 8:00 AM Albireo Pharma, Inc. (ALBO) Ultragenyx Pharmaceutical Sartorius AG (SARTF) Twist Bioscience Corporation Menlo Therapeutics Inc. NantCell, Inc. (Private) Biotechnology Inc. (RARE) MedTech (TWST) (MNLO) Biotechnology Ron Cooper, President & CEO Biotechnology Rainer Lehmann, CFO; Life Sciences Biotechnology Patrick Soon-Shiong, CEO & Shalini Sharp, CFO Ben Orzelek, Head of IR Emily Leproust, CEO Steve Basta, CEO Chairman 8:30 AM Heska Corporation (HSKA) Swedish Orphan Biovitrum QIAGEN N.V. (QGEN) Medpace Holdings, Inc. Quotient Limited (QTNT) NantKwest, Inc. (NK) Pandion Therapeutics, Inc. Animal Health AB (SOBI SS) Life Sciences (MEDP) MedTech Biotechnology (Private) Kevin Wilson, CEO & President Biotechnology Peer Schatz, CEO Healthcare Services Chris Lindop, CFO Patrick Soon-Shiong, Chairman Biotechnology Guido Oelkers, CEO August Troendle, President & & CEO Anthony Coyle, President & CEO; Jesse Geiger, CFO & CEO COO, Laboratory Operations 9:00 AM Surgery Partners, Inc. (SGRY) NovoCure Limited (NVCR) Lonza Group Ltd (LONN VX) Urogen Pharma Ltd. (URGN) miRagen Therapeutics, Inc. Lyra Therapeutics (Private) Arcutis, Inc. (Private) Healthcare Services MedTech Biotechnology Biotechnology (MGEN) Biotechnology Pharmaceuticals Tom Cowhey, CFO Bill Doyle, Executive Chairman Rodolfo Savitzky, CFO Liz Barrett, CEO Biotechnology Maria Palasis, President & CEO Frank Watanabe, President & William Marshall, President & CEO CEO 9:30 AM Knight Therapeutics Inc. Allogene Therapeutics, Inc. Cerner Corporation (CERN) Mithra Women's Health Eagle Pharmaceuticals, Inc. Scholar Rock, Inc. (SRRK) Intuity Medical, Inc. (Private) (04K GR) (ALLO) HCIT (MITRA BB) (EGRX) Pharmaceuticals MedTech Pharmaceuticals Biotechnology Marc Naughton, EVP & CFO Pharmaceuticals Pharmaceuticals Nagesh Mahanthappa, Emory Anderson, President & Samira Sakhia, President Eric Schmidt, CFO Alexandra Deschner, IR Officer Scott Tarriff, CEO; President & CEO CEO Pete Meyers, CFO 10:00 AM Addus HomeCare PRA Health Sciences, Inc. Bio-Rad Laboratories (BIO) Pacira BioSciences, Inc. Translate Bio, Inc. (TBIO) Nordic Nanovector ASA Cadent Therapeutics Corporation (ADUS) (PRAH) Life Sciences (PCRX) Biotechnology (NANO NO) (Private) Healthcare Services Healthcare Services Norman Schwartz, President; Pharmaceuticals Ronald Renaud, CEO Biotechnology Pharmaceuticals Dirk Allison, President & CEO; Colin Shannon, CEO; Ilan Daskal, CFO Dave Stack, CEO Eduardo Bravo, CEO O Jodie Morrison, CEO Brian Poff, EVP & CFO Mike Bonello, CFO 10:30 AM Surmodics, Inc. (SRDX) Retrophin, Inc. (RTRX) Teladoc Health (TDOC) Viking Therapeutics, Inc. CytomX Therapeutics, Inc. Indivior PLC (INDV LN) MedTech Biotechnology Healthcare Services (VKTX) (CTMX) Pharmaceuticals Gary Maharaj, President & Eric Dube, CEO Jason Gorevic, CEO; Biotechnology Biotechnology Shaun Thaxter, CEO CEO; Tim Arens, VP of Finance Valerie Haertel, IR Brian Lian, President & CEO Sean McCarthy, President, CEO & CFO & Chairman 11:00 AM Vanda Pharmaceuticals Inc. LivaNova PLC (LIVN) Humana Inc. (HUM) Acadia Healthcare Company, OptiNose, Inc. (OPTN) Dova Pharmaceuticals, Inc. KSQ Therapeutics, Inc. (VNDA) MedTech Healthcare Services Inc. (ACHC) Pharmaceuticals (DOVA) (Private) Biotechnology Damien McDonald, CEO Brian Kane, CFO Healthcare Services Peter Miller, CEO Pharmaceuticals Biotechnology Mihales Polymeropoulos, M.D., Debbie Osteen, CEO; David Zaccardelli, CEO David P. Meeker Meeker, CEO President & CEO; Jim Kelly, David Duckworth, CFO EVP, CFO & Treasurer 11:30 AM HMS Holdings Corp. (HMSY) H. Lundbeck A/S (LUN DC) Roche Holding AG (ROG VX) bluebird bio, Inc. (BLUE) CRISPR Therapeutics AG Establishment Labs Holdings Urovant Sciences Ltd. (UROV) Healthcare Services Pharmaceuticals Pharmaceuticals Biotechnology (CRSP) Inc. (ESTA) Pharmaceuticals Jeff Sherman, EVP & CFO Peter Anastasiou, EVP, Alan Hippe, CFO Roche Chip Baird, CFO Biotechnology MedTech Keith Katkin, President & CEO; Lundbeck North America Sam Kulkarni, CEO Nick Lewin, Chairman; Juan Cornelia Haag-Molkenteller, Jose Chacon Quiros, CEO; CMO; Michael McFadden, Renee Gaeta, CFO Chief Commercial Officer AGENDA TUESDAY, JUNE 4, 2019 Jefferies 2019 Global Healthcare Conference BALLROOM 1 BALLROOM 2 BALLROOM 3 BALLROOM 4 BALLROOM 5 MOROSCO IMPERIAL BREAKOUT: URIS BREAKOUT: JUILLIARD BREAKOUT: BROADWAY BREAKOUT: CARNEGIE HALL BREAKOUT: ALVIN BREAKOUT: PLYMOUTH BREAKOUT: BOOTH 12:00 PM Break for Lunch / Presentation Room Setup 12:15 PM KEYNOTE: “Drug Pricing: The Politics and Outlook” Ted Kennedy, Jr., Partner, Epstein Becker Green & Lynn Shapiro Snyder, Senior Member, Epstein Becker Green (12:15PM-1:00PM) 1:30 PM Fluidigm Corporation United Therapeutics Centene Corporation (CNC) Amedisys, Inc. (AMED) Xeris Pharmaceuticals, Inc. IGM Biosciences, Inc. (FLDM) Corporation (UTHR) Healthcare Services Healthcare Services (XERS) (Private) Life Sciences Biotechnology Ed Kroll, SVP, Finance & IR Paul Kusserow, CEO Pharmaceuticalsv Biotechnology Vikram Jog, CFO James Edgemond, CFO & Paul Edick, CEO Fred M. Schwarzer, CEO Treasurer 2:00 PM BioScrip, Inc. (BIOS) NextGen Healthcare, Inc. The Cooper Companies, Inc. Veloxis Pharmaceuticals A/S Bellicum Pharmaceuticals, Veru Inc. (VERU) Aura Biosciences, Inc. Healthcare Services (NXGN) (COO) (VELO DC) Inc. (BLCM) Pharmaceuticals (Private) Dan Greenleaf, President & HCIT MedTech Pharmaceuticals Biotechnology Mitchell Steiner, Chairman, Biotechnology CEO; Steve Deitsch, SVP, CFO Rusty Frantz, President & CEO Brian Andrews, SVP, CFO & Craig Collard, CEO Atabak Mokari, CFO President CEO Elisabet de los Pinos, CEO & Treasurer Treasurer 2:30 PM Ra Pharmaceuticals, Inc. MEDNAX, Inc. (MD) Mettler-Toledo International Aerie Pharmaceuticals, Inc. Corbus Pharmaceuticals Collegium Pharmaceutical, Catalyst Biosciences, Inc. (RARX) Healthcare Services Inc. (MTD) (AERI) Holdings, Inc. (CRBP) Inc. (COLL) (CBIO) Biotechnology Charles Lynch, VP, Strategy Life Sciences Pharmaceuticals Pharmaceuticals Pharmaceuticals Biotechnology Doug Treco, President & CEO Shawn Vadala, CFO Vince Anido, Chairman & CEO Yuval Cohen, CEO Joe Ciaffoni, CEO; Nassim Usman, President & Paul Brannelly, EVP & CFO CEO; Fletcher Payne, CFO; Howard Levy, CMO 3:00 PM BioArctic AB (BIOAB LN) West Pharmaceutical Hologic Inc. (HOLX) Vocera Communications, Inc. Akebia Therapeutics, Inc. Verrica Pharmaceuticals Inc. Minerva Neurosciences, Inc. Biotechnology Services, Inc. (WST) MedTech (VCRA) (AKBA) (VRCA) (NERV) Gunilla Osswald, CEO; MedTech Karleen Oberton, CFO; HCIT Biotechnology Pharmaceuticals Biotechnology Johanna Fälting, VP, Eric Green, CEO & President Michael Watts, VP, IR & Brent Lang, CEO; Sue Dooley, John Butler, CEO Ted White, President & CEO Remy Luthringer, Executive Translational Science & Corp Communications Head of IR Chairman & CEO Pharmacology 3:30 PM Banca Farmafactoring S.p.a. Corcept Therapeutics Exact Sciences Corporation Apellis Pharmaceuticals, Inc. PDL BioPharma, Inc. (PDLI) EUSA Pharma Ltd (Private) . Galapagos NV (GLPG NA) (BFF IM) Incorporated (CORT) (EXAS) (APLS) Pharmaceuticals Pharmaceuticals Biotechnology Healthcare Services Pharmaceuticals Life Sciences Biotechnology Dominique Monnet, President Lee Morley, CEO Onno van de Stolpe, CEO Massimiliano Belingheri, CEO; Joseph Belanoff, CEO Kevin Conroy, President & Cedric Francois, CEO & CEO; Peter Garcia, CFO Emanuele Bona, CFO; Enrico CEO Tadiotto, Head of IR, Strategy, M&A; Nazareno Ciccarello, Multinationals Development Manager 4:00 PM Arcus Biosciences, Inc. Luminex
Load more

Recommended publications
  • Biotech Investing 2020
    BIOTECH INVESTING 2020 Bill Cara www.billcara.com [email protected] 647-868-6013 JULY 20, 2020 A. Report Overview This Greenfield Capital (billcara.com) report on the Biotechnology industry is written by a registered investment consultant & portfolio manager, not by a scientist. Our objective is to provide education and information to investors who lack the tools to trade successfully in an industry made vitally important to the world by the coronavirus pandemic of 2020. If we want to live through this pandemic -- and future ones -- where it is possible that hundreds of millions of us could perish because of the lack of diagnostics, vaccines, and therapeutics, then as investors we should be keenly interested in the Biotech industry. News reports state that in just six and a half months, COVID-19, initially called SARS- CoV-2, has killed more people than the number of Americans who die each year from opioid overdose (46,000), traffic accidents (36,500), and gun violence (40,000) combined. But, currently, there is no vaccine for COVID-19, and the treatment options for patients with severe or life-threatening symptoms are limited. As the world struggles to contain the deadly virus, there are, fortunately, over 140 coronavirus vaccines in development. News is breaking every day. At the same time, however, many individuals who are trading in Biotech stocks remain woefully uninformed and are speculating wildly. Some Biotech stocks that have appreciated 100% or more in a few months on hopefulness may have trouble sustaining gains beyond the news peak. Still, for investors who study this industry, there are opportunities right now to buy Biotech stocks that will grow in price well into the future.
    [Show full text]
  • The Top 100 November, 2016 a List of Stocks Topping Our Custom 'Torpedo’ Screen
    The Top 100 November, 2016 A list of stocks topping our custom 'torpedo’ screen. Updated monthly. GPRO GoPro, Inc. Class A Consumer Discretionary TSLA Tesla Motors, Inc. Consumer Discretionary UA Under Armour, Inc. Class A Consumer Discretionary CRC California Resources Corp Energy CRZO Carrizo Oil & Gas, Inc. Energy CWEI Clayton Williams Energy, Inc. Energy FANG Diamondback Energy, Inc. Energy GST Gastar Exploration, Inc. Energy MPLX MPLX LP Energy RSPP RSP Permian, Inc. Energy SLCA U.S. Silica Holdings, Inc. Energy AAC AAC Holdings, Inc. Health Care ABEO Abeona Therapeutics, Inc. Health Care ACAD ACADIA Pharmaceuticals Inc. Health Care ADMP Adamis Pharmaceuticals Corporation Health Care ADMS Adamas Pharmaceuticals, Inc. Health Care ADXS Advaxis, Inc. Health Care AIMT Aimmune Therapeutics Inc Health Care AKBA Akebia Therapeutics, Inc. Health Care ALDR Alder Biopharmaceuticals, Inc. Health Care ARDM Aradigm Corporation Health Care ARDX Ardelyx, Inc. Health Care ARLZ Aralez Pharmaceuticals Inc. Health Care ATRA Atara Biotherapeutics Inc Health Care BCRX BioCryst Pharmaceuticals, Inc. Health Care BLUE bluebird bio, Inc. Health Care CARA Cara Therapeutics Inc Health Care CDNA CareDx, Inc. Health Care CEMP Cempra, Inc. Health Care CERS Cerus Corporation Health Care CFMS ConforMIS Inc Health Care CLVS Clovis Oncology, Inc. Health Care COLL Collegium Pharmaceutical, Inc. Health Care CORI Corium International, Inc. Health Care CRMD CorMedix Inc. Health Care CSU Capital Senior Living Corporation Health Care DERM Dermira Inc Health Care DVAX Dynavax Technologies Corporation Health Care DXCM DexCom, Inc. Health Care EPZM Epizyme, Inc. Health Care FOLD Amicus Therapeutics, Inc. Health Care HRTX Heron Therapeutics Inc Health Care ICPT Intercept Pharmaceuticals, Inc.
    [Show full text]
  • NASDAQ Stock Market
    Nasdaq Stock Market Friday, December 28, 2018 Name Symbol Close 1st Constitution Bancorp FCCY 19.75 1st Source SRCE 40.25 2U TWOU 48.31 21st Century Fox Cl A FOXA 47.97 21st Century Fox Cl B FOX 47.62 21Vianet Group ADR VNET 8.63 51job ADR JOBS 61.7 111 ADR YI 6.05 360 Finance ADR QFIN 15.74 1347 Property Insurance Holdings PIH 4.05 1-800-FLOWERS.COM Cl A FLWS 11.92 AAON AAON 34.85 Abiomed ABMD 318.17 Acacia Communications ACIA 37.69 Acacia Research - Acacia ACTG 3 Technologies Acadia Healthcare ACHC 25.56 ACADIA Pharmaceuticals ACAD 15.65 Acceleron Pharma XLRN 44.13 Access National ANCX 21.31 Accuray ARAY 3.45 AcelRx Pharmaceuticals ACRX 2.34 Aceto ACET 0.82 Achaogen AKAO 1.31 Achillion Pharmaceuticals ACHN 1.48 AC Immune ACIU 9.78 ACI Worldwide ACIW 27.25 Aclaris Therapeutics ACRS 7.31 ACM Research Cl A ACMR 10.47 Acorda Therapeutics ACOR 14.98 Activision Blizzard ATVI 46.8 Adamas Pharmaceuticals ADMS 8.45 Adaptimmune Therapeutics ADR ADAP 5.15 Addus HomeCare ADUS 67.27 ADDvantage Technologies Group AEY 1.43 Adobe ADBE 223.13 Adtran ADTN 10.82 Aduro Biotech ADRO 2.65 Advanced Emissions Solutions ADES 10.07 Advanced Energy Industries AEIS 42.71 Advanced Micro Devices AMD 17.82 Advaxis ADXS 0.19 Adverum Biotechnologies ADVM 3.2 Aegion AEGN 16.24 Aeglea BioTherapeutics AGLE 7.67 Aemetis AMTX 0.57 Aerie Pharmaceuticals AERI 35.52 AeroVironment AVAV 67.57 Aevi Genomic Medicine GNMX 0.67 Affimed AFMD 3.11 Agile Therapeutics AGRX 0.61 Agilysys AGYS 14.59 Agios Pharmaceuticals AGIO 45.3 AGNC Investment AGNC 17.73 AgroFresh Solutions AGFS 3.85
    [Show full text]
  • CDER – Redi: Focus on CGMP & FDA Inspections – Participant List
    FDA – CDER – RedI: Focus on CGMP & FDA Inspections – Participant List These participants granted permission to share their contact information Eileen Zhou Michael Channing A B M Mahfuz ul Alam Research Associate Group Chief - Positron Emission General Manager, Quality Operations Neuralstem Tomography Department ACI HealthCare Limited Germantown, MD, United States NIH Dhaka, Non-US, Bangladesh [email protected] Bethesda, MD, United States [email protected] [email protected] Abe Wong ABHIJEET GUJAR Adam Ebbinghouse CCO Chief Operating Officer QC Associate Gmpsigma SETHU KP Pharmaceutical Technology, Inc. Seattle, WA, United States Porvorim Goa, Non-US, India Bloomington, IN, United States [email protected] [email protected] [email protected] Adil Gatrad Adiseshu Modugula Aditiben Patel Director, Quality Systems RA Regulatory Specialist Actavis MSN USAMMDA Parsippany, NJ, United States Hyderabad, Non-US, India Frederick, MD, United States [email protected] [email protected] [email protected] Adriana de la Cruz ahsanul haque Aimee Gogarty Manager CSO Quality Coordinator Laboratorios Pisa SA de CV FDA Mallinckrodt Jalisco, Non-US, Mexico silver spring, MD, United States Port Allen, LA, United States [email protected] [email protected] [email protected] Aislyn Fronzak Ajay Deshmukh Ajay Khedkar QC Manager QA manager Regulatory Affair PL Developments Ingenus Pharmaceutical Umedica Laboratories Pvt Ltd Clinton, SC, United States Navi mumbai, Non-US, India Mumbai, Non-US, India [email protected]
    [Show full text]
  • 11/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 20:25:21 Report Id 2794D051 Page: 01
    MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 11/09/2016 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 20:25:21 REPORT ID 2794D051 PAGE: 01 NUMERIC COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 01/01/2017 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 00002 ELI LILLY AND COMPANY 00145 STIEFEL LABORATORIES, INC, 00003 E.R. SQUIBB & SONS, LLC. 00149 WARNER CHILCOTT PHARMACEUTICALS INC. 00004 HOFFMANN-LA ROCHE 00168 E FOUGERA AND CO. 00006 MERCK & CO., INC. 00169 NOVO NORDISK, INC. 00007 GLAXOSMITHKLINE 00172 IVAX PHARMACEUTICALS, INC. 00008 WYETH LABORATORIES 00173 GLAXOSMITHKLINE 00009 PFIZER, INC 00178 MISSION PHARMACAL COMPANY 00013 PFIZER, INC. 00182 GOLDLINE LABORATORIES, INC. 00015 MEAD JOHNSON AND COMPANY 00185 EON LABS, INC. 00023 ALLERGAN INC 00186 ASTRAZENECA LP 00024 SANOFI-AVENTIS, US LLC 00187 VALEANT PHARMACEUTICALS NORTH AMERICA 00025 PFIZER, INC. 00206 LEDERLE PIPERACILLIN 00026 BAYER HEALTHCARE LLC 00224 KONSYL PHARMACEUTICALS, INC. 00029 GLAXOSMITHKLINE 00225 B. F. ASCHER AND COMPANY, INC. 00032 SOLVAY PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 00037 MEDA PHARMACEUTICALS, INC. 00245 UPSHER-SMITH LABORATORIES, INC. 00039 SANOFI-AVENTIS, US LLC 00258 FOREST LABORATORIES INC 00046 AYERST LABORATORIES 00259 MERZ PHARMACEUTICALS 00049 PFIZER, INC 00264 B. BRAUN MEDICAL INC. 00051 UNIMED PHARMACEUTICALS, INC 00281 SAVAGE LABORATORIES 00052 ORGANON USA INC. 00299 GALDERMA LABORATORIES, L.P. 00053 CSL BEHRING 00300 TAP PHARMACEUTICALS INC 00054 ROXANE LABORATORIES, INC. 00310 ASTRAZENECA LP 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00327 GUARDIAN LABS DIV UNITED-GUARDIAN INC 00062 ORTHO MCNEIL PHARMACEUTICALS 00338 BAXTER HEALTHCARE CORPORATION 00064 HEALTHPOINT, LTD. 00378 MYLAN PHARMACEUTICALS, INC.
    [Show full text]
  • Fidelity® Select Portfolio® Biotechnology Portfolio
    Quarterly Holdings Report for Fidelity® Select Portfolio® Biotechnology Portfolio May 31, 2021 BIO-QTLY-0721 1.802156.117 Schedule of Investments May 31, 2021 (Unaudited) Showing Percentage of Net Assets Common Stocks – 97.4% Shares Value Shares Value Biotechnology – 89.4% CareDx, Inc. (a) 178,500 $ 14,351,400 Biotechnology – 89.4% Celldex Therapeutics, Inc. (a) 337,900 9,444,305 4D Molecular Therapeutics, Inc. 214,868 $ 5,706,894 Cellectis SA sponsored ADR (a) (b) 157,465 2,467,477 AbbVie, Inc. 9,829,284 1,112,674,949 Cerevel Therapeutics Holdings (a) 201,800 2,647,616 ACADIA Pharmaceuticals, Inc. (a) 199,594 4,458,930 ChemoCentryx, Inc. (a) 2,062,222 20,931,553 Acceleron Pharma, Inc. (a) 924,453 121,001,653 Chinook Therapeutics, Inc. (a) 840,646 13,870,659 ADC Therapeutics SA (a) (b) 755,238 16,350,903 Chinook Therapeutics, Inc. rights (a) (d) 115,821 5,791 Agios Pharmaceuticals, Inc. (a) 1,075,059 59,966,791 Codiak Biosciences, Inc. (b) 436,539 9,874,512 Akouos, Inc. (a) (b) 716,626 9,359,136 Coherus BioSciences, Inc. (a) 58,387 768,373 Albireo Pharma, Inc. (a) (b) 320,350 10,715,708 Connect Biopharma Holdings Ltd. ADR (a) 1,079,600 16,064,448 Aldeyra Therapeutics, Inc. (a) 1,201,911 15,047,926 Constellation Pharmaceuticals, Inc. (a) (b) 90,259 1,788,031 Alector, Inc. (a) (b) 998,482 17,772,980 ContraFect Corp. (a) (b) 456,309 1,843,488 Allakos, Inc. (a) 207,631 21,062,089 Cortexyme, Inc.
    [Show full text]
  • Active Labelers Run Date : Feb 19, 2018
    Active Labelers Run Date : Feb 19, 2018 Labeler ID Labeler Name Contract Begin Date Contract End Date 00002 ELI LILLY AND COMPANY 01/01/1991 01/01/3000 00003 E.R. SQUIBB & SONS, LLC. 01/01/1991 01/01/3000 00004 HOFFMANN-LA ROCHE 01/01/1991 01/01/3000 00006 MERCK & CO., INC. 01/01/1991 01/01/3000 00007 GLAXOSMITHKLINE 01/01/1991 01/01/3000 00008 WYETH LABORATORIES 01/01/1991 01/01/3000 00009 PFIZER, INC 01/01/1991 01/01/3000 00013 PFIZER, INC. 01/01/1991 01/01/3000 00014 PFIZER, INC 01/01/1991 01/01/3000 00015 MEAD JOHNSON AND COMPANY 01/01/1991 01/01/3000 00023 ALLERGAN INC 01/01/1991 01/01/3000 00024 SANOFI-AVENTIS, US LLC 01/01/1991 01/01/3000 00025 PFIZER, INC. 01/01/1991 01/01/3000 00026 BAYER HEALTHCARE LLC 01/01/1991 01/01/3000 00029 GLAXOSMITHKLINE 01/01/1991 01/01/3000 00032 ABBVIE INC. 01/01/1991 01/01/3000 00037 MEDA PHARMACEUTICALS, INC. 01/01/1991 01/01/3000 00039 SANOFI-AVENTIS, US LLC 01/01/1991 01/01/3000 00046 AYERST LABORATORIES 01/01/1991 01/01/3000 00049 PFIZER, INC 01/01/1991 01/01/3000 00051 ABBVIE INC 10/01/1997 01/01/3000 00052 ORGANON USA INC. 01/01/1991 01/01/3000 00053 CSL BEHRING LLC 01/01/1991 01/01/3000 00054 WEST-WARD PHARMACEUTICALS CORP. 01/01/1991 01/01/3000 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 01/01/1991 01/01/3000 00062 ORTHO MCNEIL PHARMACEUTICALS 01/01/1991 01/01/3000 00064 HEALTHPOINT, LTD.
    [Show full text]
  • 2016 Medicines in Development for Rare Diseases a LIST of ORPHAN DRUGS in the PIPELINE
    2016 Medicines in Development for Rare Diseases A LIST OF ORPHAN DRUGS IN THE PIPELINE Autoimmune Diseases Product Name Sponsor Official FDA Designation* Development Status Actemra® Genentech treatment of systemic sclerosis Phase III tocilizumab South San Francisco, CA www.gene.com Adempas® Bayer HealthCare Pharmaceuticals treatment of systemic sclerosis Phase II riociguat Whippany, NJ www.pharma.bayer.com ARA 290 Araim Pharmaceuticals treatment of neuropathic pain in patients Phase II Tarrytown, NY with sarcoidosis www.ariampharma.com ARG201 arGentis Pharmaceuticals treatment of diffuse systemic sclerosis Phase II (type 1 native bovine skin Collierville, TN www.argentisrx.com collagen) BYM338 Novartis Pharmaceuticals treatment of inclusion body myositis Phase III (bimagrumab) East Hanover, NJ www.novartis.com CCX168 ChemoCentryx treatment of anti-neutrophil cytoplasmic Phase II (5a receptor antagonist) Mountain View, CA auto-antibodies associated vasculitides www.chemocentryx.com (granulomatosis with polyangitis or Wegener's granulomatosis), microscopic polyangitis, and Churg-Strauss syndrome * This designation is issued by the FDA's Office of Orphan Products Development while the drug is still in development. The designation makes the sponsor of the drug eligible for entitlements under the Orphan Drug Act of 1983. The entitlements include seven years of marketing exclusivity following FDA approval of the drug for the designated use. Medicines in Development: Rare Diseases | 2016 1 Autoimmune Diseases Product Name Sponsor Official FDA
    [Show full text]
  • Rebateable Manufacturers
    Rebateable Labelers – July 2021 Manufacturers are responsible for updating their eligible drugs and pricing with CMS. Montana Healthcare Programs will not pay for an NDC not updated with CMS. Note: Some manufacturers on this list may have some NDCs that are covered and others that are not. Manufacturer ID Manufacturer Name 00002 ELI LILLY AND COMPANY 00003 E.R. SQUIBB & SONS, LLC. 00004 HOFFMANN-LA ROCHE 00006 MERCK & CO., INC. 00007 GLAXOSMITHKLINE 00008 WYETH PHARMACEUTICALS LLC, 00009 PHARMACIA AND UPJOHN COMPANY LLC 00013 PFIZER LABORATORIES DIV PFIZER INC 00015 MEAD JOHNSON AND COMPANY 00023 ALLERGAN INC 00024 SANOFI-AVENTIS, US LLC 00025 PFIZER LABORATORIES DIV PFIZER INC 00026 BAYER HEALTHCARE LLC 00032 ABBVIE INC. 00037 MEDA PHARMACEUTICALS, INC. 00039 SANOFI-AVENTIS, US LLC 00046 WYETH PHARMACEUTICALS INC. 00049 ROERIG 00051 ABBVIE INC 00052 ORGANON USA INC. 00053 CSL BEHRING L.L.C. 00054 HIKMA PHARMACEUTICAL USA, INC. 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00065 ALCON LABORATORIES, INC. 00068 AVENTIS PHARMACEUTICALS 00069 PFIZER LABORATORIES DIV PFIZER INC 00071 PARKE-DAVIS DIV OF PFIZER 00074 ABBVIE INC 00075 AVENTIS PHARMACEUTICALS, INC. 00078 NOVARTIS 00085 SCHERING CORPORATION 00087 BRISTOL-MYERS SQUIBB COMPANY 00088 AVENTIS PHARMACEUTICALS 00093 TEVA PHARMACEUTICALS USA, INC. 00095 BAUSCH HEALTH US, LLC Page 1 of 19 Manufacturer ID Manufacturer Name 00096 PERSON & COVEY, INC. 00113 L. PERRIGO COMPANY 00115 IMPAX GENERICS 00116 XTTRIUM LABORATORIES, INC. 00121 PHARMACEUTICAL ASSOCIATES, INC. 00131 UCB, INC. 00132 C B FLEET COMPANY INC 00143 HIKMA PHARMACEUTICAL USA, INC. 00145 STIEFEL LABORATORIES, INC, 00168 E FOUGERA AND CO. 00169 NOVO NORDISK, INC. 00172 TEVA PHARMACEUTICALS USA, INC 00173 GLAXOSMITHKLINE 00178 MISSION PHARMACAL COMPANY 00185 EON LABS, INC.
    [Show full text]
  • BIOCRYST PHARMACEUTICALS, INC. (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2005 OR o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from ___________ to ___________. Commission File Number 000-23186 BIOCRYST PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 62-1413174 (State of other jurisdiction of incorporation or organization) (I.R.S. employer identification no.) 2190 Parkway Lake Drive; Birmingham, Alabama 35244 (Address of principal executive offices) (205) 444-4600 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered None None Securities registered pursuant to Section 12(g) of the Act: Title of each class Common Stock, $.01 Par Value Indicate by a check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes o Nox. Indicate by a check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o Nox. Indicate by a check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • BIOCRYST PHARMACEUTICALS, INC. 4505 Emperor Blvd., Suite 200 Durham, North Carolina 27703
    BIOCRYST PHARMACEUTICALS, INC. 4505 Emperor Blvd., Suite 200 Durham, North Carolina 27703 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held June 20, 2018 To the Stockholders of BioCryst Pharmaceuticals, Inc.: Notice is hereby given that the Annual Meeting of Stockholders of BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), will be held at our corporate offices at 4505 Emperor Blvd., Suite 200, Durham, NC 27703 on Wednesday, June 20, 2018 at 10:00 a.m., Eastern Daylight Time (the “Meeting”), for the following purposes: 1. To elect the two directors nominated in this Proxy Statement to serve for a term of three years and until a successor is duly elected and qualified; 2. To ratify the selection of Ernst & Young LLP as our independent registered public accountants for 2018; 3. To hold an advisory vote approving the Company’s executive compensation; 4. To transact such other business as may properly come before the Meeting or any adjournment thereof. THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE IN FAVOR OF PROPOSALS 1, 2 AND 3. The proposals are further described in the Proxy Statement. The Board of Directors has fixed the close of business on May 2, 2018 as the record date for the determination of stockholders entitled to receive notice of and to vote at the Meeting or any adjournment thereof. The Meeting may be adjourned from time to time without notice other than announcement at the Meeting, and any business for which notice of the Meeting is hereby given may be transacted at any such adjournment. A list of the stockholders entitled to vote at the Meeting will be open to examination by any stockholder, for any purpose germane to the Meeting, during ordinary business hours, for a period of at least ten days prior to the Meeting at the principal executive offices of the Company in Durham, North Carolina.
    [Show full text]
  • Biocryst Pharmaceuticals Inc
    BIOCRYST PHARMACEUTICALS INC FORM 10-K (Annual Report) Filed 3/9/2006 For Period Ending 12/31/2005 Address 2190 PARKWAY LAKE DR BIRMINGHAM, Alabama 35244 Telephone 205-444-4600 CIK 0000882796 Industry Biotechnology & Drugs Sector Healthcare Fiscal Year 12/20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2005 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from ___________ to ___________. Commission File Number 000-23186 BIOCRYST PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 62 -1413174 (State of other jurisdiction of incorporation or organization) (I.R.S. employer identification no.) 2190 Parkway Lake Drive; Birmingham, Alabama 35244 (Address of principal executive offices) (205) 444-4600 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered None None Securities registered pursuant to Section 12(g) of the Act: Title of each class Common Stock, $.01 Par Value Indicate by a check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No . Indicate by a check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No . Indicate by a check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]